Day: March 2, 2020

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

Written by Customer Service on March 2, 2020. Posted in Earnings Releases And Operating Results.

NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ending December 31, 2019, and provided a corporate update.“We are very excited about the recent FDA approval of CAPLYTA™ (lumateperone) for the treatment of schizophrenia and we are fully prepared for our planned commercial launch later this month,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “We have also continued to advance our pipeline programs in 2019 and anticipate a number of meaningful developments in 2020, including reporting topline data from our lumateperone Phase 3 trial in bipolar depression and topline...

MJ Holdings 2019 Grow Results Exceeding Expectations

Written by Customer Service on March 2, 2020. Posted in Public Companies.

Las Vegas, NV, March 02, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — MJ Holdings, Inc. (OTCPK: MJNE) (the “Company”), a leader in the Nevada cannabis market, completed our second annual managed grow and harvest in November 2019. The initial test grow was completed in late 2018 and yielded just over 5,500 lbs. of dried and tested marijuana trim. In late December of 2019 the first 80 lbs. of flower was sold under our Highland Brothers brand for over $118,000, a more than 1,500% increase in revenue over December of 2018. In 2019 we planted less marijuana in an effort to more closely monitor the cultivation of the plants and concentrate on the curing process. The preliminary results from our 2019 managed grow are even better than we expected with nearly 1,700 lbs. of marijuana flower and popcorn bud tested at between 16% and 26%...

Teleste to initiate co-determination negotiations

Written by Customer Service on March 2, 2020. Posted in Public Companies.

TELESTE CORPORATION INVESTOR NEWS 2.3.2020 AT 14:10 EETTELESTE TO INITIATE CO-DETERMINATION NEGOTIATIONSTeleste Corporation will initiate co-determination negotiations in accordance with the Act on Co-operation within Undertakings in order to adapt its operations. The negotiations may lead to possible redundancies, temporary lay-offs and part-time employment contracts due to production and financial reasons.The reason for the adjustments is the ongoing technological transformation in the Network Products business area that has led to decreased demand for traditional access network products, as stated in the 2019 financial statement release. This change decreases the related capacity need in production and supporting functions. According to our estimate, the deliveries of distributed access architecture products will commence during...

Teleste käynnistää YT-neuvottelut

Written by Customer Service on March 2, 2020. Posted in Public Companies.

TELESTE OYJ SIJOITTAJAUUTINEN 2.3.2020 KLO 14:10TELESTE KÄYNNISTÄÄ YT-NEUVOTTELUTTeleste Oyj aloittaa yhteistoimintalain mukaiset neuvottelut toimenpiteistä, joiden tavoitteena on toiminnan sopeuttaminen, mikä johtaa mahdollisiin irtisanomisiin, lomautuksiin ja osa-aikaisuuksiin tuotannollisista ja taloudellisista syistä.Sopeuttamistarpeen syynä on teknologiamurroksen seurauksena Network Products -liiketoimintaan kuuluvien tilaajaverkkotuotteiden kysynnän muutos, kuten vuoden 2019 tilinpäätöstiedotteessa todettiin. Tämä muutos vähentää tuotannon ja tukitoimintojen kapasiteetin tarvetta. Yhtiön ennusteen mukaan hajautetun verkkoarkkitehtuurin tuotteiden toimitukset käynnistyvät loppuvuonna. Näiden uusien tuotteiden valmistus ei kuitenkaan edellytä vähennystarvetta vastaavaa tuotantokapasiteettia.Neuvottelut koskevat Teleste Oyj:n...

Wave Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Written by Customer Service on March 2, 2020. Posted in Earnings Releases And Operating Results.

Innovative pipeline of stereopure oligonucleotides focused on CNS diseases32 mg data from both PRECISION-HD clinical trials on track for 2H 2020Two additional CNS programs − SNP3 and C9orf72 − on track to initiate clinical development in 2H 2020Wave to host investor conference call and webcast at 8:00 a.m. ET todayCAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the fourth quarter and full year ended December 31, 2019 and provided a business update.Business updateWave is building a leading genetic medicines company focused on realizing the potential of stereopure oligonucleotides in diseases of the central nervous system,...

Neon Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Written by Customer Service on March 2, 2020. Posted in Earnings Releases And Operating Results.

CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN) today reported financial results for the fourth quarter and full-year ended December 31, 2019 and provided a business update.“Earlier this year, we were delighted to announce our entry into a definitive merger agreement with BioNTech. Once closed, the transaction will combine two organizations with a common culture of pioneering translational science and a shared vision for the future of cancer immunotherapy,” said Hugh O’Dowd, Chief Executive Officer of Neon. “We continue to be encouraged by the potential of our novel neoantigen-targeted T cell therapies and are confident that this merger with BioNTech will provide the foundation from which to ensure that potential will be realized.”BioNTech Transaction DetailsUnder the terms of the definitive...

Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates

Written by Customer Service on March 2, 2020. Posted in Earnings Releases And Operating Results.

2019 Galafold Revenue Nearly Doubled to $182.2MOn Track to Achieve 2020 Revenue Guidance of $250M-$260MFocused on Pompe Phase 3 PROPEL Study, Manufacturing to Support 2021 BLA and MAA, and Accelerating Expanded Access Program for Infantile-Onset PatientsAdvancing Industry-Leading Rare Disease Gene Therapy PortfolioStrong Balance Sheet with $450M+ Cash – Cash Runway Well into 2022Conference Call and Webcast Today at 8:30 a.m. ETCRANBURY, N.J., March 02, 2020 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2019. The Company also summarized recent program updates and reiterated its full-year 2020 guidance.Corporate Highlights...

Oxford Immunotec Reports Fourth Quarter and Full Year 2019 Financial Results

Written by Customer Service on March 2, 2020. Posted in Earnings Releases And Operating Results.

Fourth quarter 2019 revenue of $18.1 million, an increase of 18% compared to the prior year periodFourth quarter 2019 gross margin of 78.3%, an increase of 410 basis points from the prior year periodFourth quarter 2019 net loss of $1.6 million, as compared to a pro forma (see tables below) net loss of $6.9 million in the prior year periodOXFORD, United Kingdom and MARLBOROUGH, Mass., March 02, 2020 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq: OXFD), or the Company, a global, high-growth diagnostics company, today announced fourth quarter and full year 2019 financial results.“The fourth quarter represents another quarter of strong revenue growth, and improving profitability metrics” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “The Company continues to see the global tuberculosis market expanding...

Semiconductor Market to Reach USD 730.29 billion by 2026; Growing Adoption of Electronics to Augment Growth, states Fortune Business Insights™

Written by Customer Service on March 2, 2020. Posted in Mergers And Acquisitions.

Pune, March 02, 2020 (GLOBE NEWSWIRE) — The global Semiconductor Market is projected to reach USD 730.29 billion by 2026, exhibiting a CAGR of 5.2% during the forecast period. The increasing utilization and consumption of consumer electronic devices will fuel demand for semiconductors during the forecast period. Furthermore, the rising demand for advanced semiconductor chips in the industrial application will contribute positively to the semiconductor market growth in the forthcoming years. In addition, the penetration of smartphones will fuel demand for semiconductors, which in turn will boost the semiconductor market revenue.According to the report, published by Fortune Business Insights, titled “Semiconductor Market Size, Share & Industry Analysis, By Components (Memory Devices, Logic Devices, Analog IC, MPU, Discrete Power...

USI Insurance Services Acquires Full Service Insurance Agency, Inc.

Written by Customer Service on March 2, 2020. Posted in Mergers And Acquisitions.

VALHALLA, N.Y., March 02, 2020 (GLOBE NEWSWIRE) — USI Insurance Services (“USI”), a world leader in risk management, employee benefit and retirement plan consulting, today announced the acquisition of Franklin, Tennessee-based Full Service Insurance Agency, Inc. Founded in 1975, Full Service Insurance is one of middle Tennessee’s leading independent insurance agencies, specializing in commercial insurance, employee benefits and personal risk solutions for businesses and individuals. Terms of the transaction were not disclosed.Commenting on the announcement, Paul Pratt, Jr., president, Full Service Insurance, stated: “Joining forces with USI, one of the world’s leading risk management, insurance brokerage and consulting organizations, marks an exciting milestone for our firm. I am confident this new partnership will further strengthen...

Day: March 2, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals